In the latest quarter, 6 analysts provided ratings for AnaptysBio (NASDAQ:ANAB), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 3 | 2 | 1 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 0 | 1 | 0 | 0 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 2 | 1 | 1 | 0 | 0 |
Analysts have set 12-month price targets for AnaptysBio, revealing an average target of $57.83, a high estimate of $90.00, and a low estimate of $30.00. Marking an increase of 9.8%, the current average surpasses the previous average price target of $52.67.
Breaking Down Analyst Ratings: A Detailed Examination
The analysis of recent analyst actions sheds light on the perception of AnaptysBio by financial experts...
Login or create a forever free account to read this news
Sign up/Log in